Earlier this year, LabGenius in partnership with Ditchley brought together a group of biotech founders, government policy makers, specialist investors and pharmaceutical experts to consider the challenges and opportunities presented by the accelerating progress in ML-enabled drug discovery.
The highlights from that discussion are included in the attached summary report.